N-Fused Imidazoles As Novel Anticancer Agents That Inhibit Catalytic Activity of Topoisomerase IIα and Induce Apoptosis in G1/S Phase

Ashish T. Baviskar; Chetna Madaan; Ranjan Preet; Purusottam Mohapatra; Vaibhav Jain; Amit Agarwal; Sankar K. Guchhait; Chanakya N. Kundu; Uttam C. Banerjee; Prasad V. Bharatam

doi:10.1021/jm200235u

journal article Jun 23, 2011

N-Fused Imidazoles As Novel Anticancer Agents That Inhibit Catalytic Activity of Topoisomerase IIα and Induce Apoptosis in G1/S Phase

Ashish T. Baviskar Chetna Madaan Ranjan Preet Purusottam Mohapatra Vaibhav Jain

Amit Agarwal

Sankar K. Guchhait Chanakya N. Kundu Uttam C. Banerjee Prasad V. Bharatam

Journal of Medicinal Chemistry Vol. 54 No. 14 pp. 5013-5030 · American Chemical Society (ACS)

View at Publisher Save 10.1021/jm200235u

Topics

No keywords indexed for this article. Browse by subject →

References

78

[1]

Andoh T. (2003) 10.1007/978-1-4615-0141-1

[2]

Nitiss J. L. Nature Rev. Cancer (2009) 10.1038/nrc2607

[3]

Wang H. K. Med. Res. Rev. (1997) 10.1002/(sici)1098-1128(199707)17:4<367::aid-med3>3.0.co;2-u

[4]

Haglof K. J. Update Cancer Ther. (2006) 10.1016/j.uct.2006.05.010

[5]

Pommier Y. Chem. Rev. (2009) 10.1021/cr900097c

[6]

Hande K. R. Biochim. Biophys. Acta (1998) 10.1016/s0167-4781(98)00134-1

[7]

Etoposide: four decades of development of a topoisomerase II inhibitor

K.R Hande

European Journal of Cancer 1998 10.1016/s0959-8049(98)00228-7

[8]

Zunino F. Anti-Cancer Drug Discovery (1990)

[9]

Nitiss J. L. Cancer Res. (1992)

[10]

Pommier Y. Nature Rev. Cancer (2006) 10.1038/nrc1977

[11]

Thomas C. J. Bioorg. Med. Chem. (2004) 10.1016/j.bmc.2003.11.036

[12]

Salerno S. Curr. Med. Chem. (2010) 10.2174/092986710793361252

[13]

Wang J. C. Nature Rev. Mol. Cell Biol. (2002) 10.1038/nrm831

[14]

Nitiss J. L. Nature Rev. Cancer (2009) 10.1038/nrc2608

[15]

Champoux J. J. Annu. Rev. Biochem. (2001) 10.1146/annurev.biochem.70.1.369

[16]

Goto T. J. Biol. Chem. (1982) 10.1016/s0021-9258(19)83859-0

[17]

Stewart L. Science (1998) 10.1126/science.279.5356.1534

[18]

Li Y. Y. Proc. Natl. Acad. Sci. U.S.A. (2002) 10.1073/pnas.222494999

[19]

Brown P. O. Science (1979) 10.1126/science.227059

[20]

Woessner R. D. Cell Growth Differ. (1991)

[21]

Issacs R. J. Biochim. Biophys. Acta (1998) 10.1016/s0167-4781(98)00131-6

[22]

Bromberg K. D. J. Biol. Chem. (2003) 10.1074/jbc.m212056200

[23]

Austin C. A. BioEssays (1998) 10.1002/(sici)1521-1878(199803)20:3<215::aid-bies5>3.0.co;2-q

[24]

Gatto B. Curr. Med. Chem. Anti-Cancer Agents (2003) 10.2174/1568011033482486

[25]

Hande K. R. Update Cancer Ther. (2008) 10.1016/j.uct.2008.02.001

[26]

McClendon A. K. Mutat. Res. (2007) 10.1016/j.mrfmmm.2007.06.009

[27]

Winick N. J. J. Clin. Oncol. (1993) 10.1200/jco.1993.11.2.209

[28]

Larsen A. K. Pharmacol. Ther. (2003) 10.1016/s0163-7258(03)00058-5

[29]

Huang H. J. Med. Chem. (2010) 10.1021/jm9014394

[30]

Jiménez-Alonso S. J. Med. Chem. (2008) 10.1021/jm800499x

[31]

Yoshida M. Clin. Cancer Res. (1999)

[32]

Weiss G. Gen. Pharm. (1999) 10.1016/s0306-3623(98)00100-1

[33]

Lang J. Y. Clin. Cancer Res. (2005) 10.1158/1078-0432.ccr-04-2026

[34]

Mashimo T. Biochem. Biophys. Res. Commun. (2000) 10.1006/bbrc.2000.3139

[35]

Chang X. Carcinogenesis (2005) 10.1093/carcin/bgi018

[36]

Chow K. C. Mol. Pharmacol. (1988) 10.1016/s0026-895x(25)08647-x

[37]

Pinar A. Biochem. Biophys. Res. Commun. (2004) 10.1016/j.bbrc.2004.03.093

[38]

Tekiner-Gulbas B. SAR QSAR Environ. Res. (2006) 10.1080/10659360600636105

[39]

Chernyak D. Angew. Chem., Int. Ed. (2010) 10.1002/anie.200907291

[40]

Jin Y. Bull. Korean Chem. Soc. (2009) 10.5012/bkcs.2009.30.6.1297

[41]

Guchhait, S. K.; Kundu, C. N.; Banerjee, U. C.; Baviskar, A.; Madaan, C.; Agarwal, A.; Preet, R.; Mohapatra, P.N-Fused aminoimidazoles as novel topoisomerase IIα-targeting anticancer agents. Indian Patent, application no. 91/DEL/2011, 2011.

[42]

Guchhait S. K. Tetrahedron Lett. (2009) 10.1016/j.tetlet.2009.09.125

[43]

Guchhait S. K. Synlett (2009) 10.1055/s-0028-1087915

[44]

Guchhait S. K. Synthesis (2009) 10.1055/s-0029-1216916

[45]

Guchhait S. K. Org. Biomol. Chem. (2010) 10.1039/c0ob00022a

[46]

Besterman J. M. J. Biol. Chem. (1989) 10.1016/s0021-9258(18)94179-7

[47]

Burres N. S. Cancer Res. (1989)

[48]

A Fast Flexible Docking Method using an Incremental Construction Algorithm

Matthias Rarey, Bernd Kramer, Thomas Lengauer et al.

Journal of Molecular Biology 1996 10.1006/jmbi.1996.0477

[49]

SYBYL 7.1;Tripos Inc.:St. Louis, MO 63144.

[50]

Wei H. J. Biol. Chem. (2005) 10.1074/jbc.m506520200

Showing 50 of 78 references

Cited By

276

Identification of pyrazole-acrylonitrile derivatives as potential anticancer agents and mechanistic insights

K. Fabitha, Munugala Chandrakanth · 2025

Bioorganic & Medicinal Chemistr...

Synergistic catalysis on Fe–Nx sites and Fe nanoparticles for efficient synthesis of quinolines and quinazolinones via oxidative coupling of amines and aldehydes

Zhiming Ma, Tao Song · 2019

Chemical Science

Design, Synthesis, and Cytotoxicity Evaluation of 3‐(5‐(3‐(aryl)‐1‐phenyl‐1H‐pyrazol‐4‐yl)‐1‐phenyl‐4,5‐dihydro‐1H‐pyrazol‐3‐yl)pyridine and 5‐(3‐(aryl)‐1‐phenyl‐1H‐pyrazol‐4‐yl)‐3‐(pyridin‐3‐yl)‐4,5‐dihydropyrazole‐1‐carbaldehyde Derivatives as Potential Anticancer Agents

Raquib Alam, Md. Aftab Alam · 2016

Journal of Heterocyclic Chemistry

Regioselective Oxidative C–H Phosphonation of Imidazo[1,2‐a]pyridines and Related Heteroarenes Mediated by Manganese(III) Acetate

Mahipal Yadav, Saidulu Dara · 2015

European Journal of Organic Chemist...

3-Formylchromone based topoisomerase IIα inhibitors: discovery of potent leads

Satyajit Singh, Ashish Triambak Baviskar · 2013

MedChemComm

Metrics

276

Citations

78

References

Details

Published: Jun 23, 2011
Vol/Issue: 54(14)
Pages: 5013-5030

Authors

A

Ashish T. Baviskar

National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab-160062, India

C

Chetna Madaan

National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab-160062, India

R

Ranjan Preet

School of Biotechnology, KIIT University, Campus-11, Patia, Bhubaneswar, Orissa-751024, India

P

Purusottam Mohapatra

School of Biotechnology, KIIT University, Campus-11, Patia, Bhubaneswar, Orissa-751024, India

V

Vaibhav Jain

National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab-160062, India

A

Amit Agarwal

National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab-160062, India

S

Sankar K. Guchhait

National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab-160062, India

C

Chanakya N. Kundu

School of Biotechnology, KIIT University, Campus-11, Patia, Bhubaneswar, Orissa-751024, India

U

Uttam C. Banerjee

National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab-160062, India

P

Prasad V. Bharatam

National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab-160062, India

Cite This Article

Ashish T. Baviskar, Chetna Madaan, Ranjan Preet, et al. (2011). N-Fused Imidazoles As Novel Anticancer Agents That Inhibit Catalytic Activity of Topoisomerase IIα and Induce Apoptosis in G1/S Phase. Journal of Medicinal Chemistry, 54(14), 5013-5030. https://doi.org/10.1021/jm200235u

N-Fused Imidazoles As Novel Anticancer Agents That Inhibit Catalytic Activity of Topoisomerase IIα and Induce Apoptosis in G1/S Phase

You May Also Like